Abstract:The apicomplexan parasite Cryptosporidium is a leading cause of childhood diarrhea in developing countries. Current treatment options are inadequate and multiple preclinical compounds are being actively pursued as potential drugs for cryptosporidiosis. Unlike most apicomplexans, Cryptosporidium spp. sequentially replicate asexually and then sexually within a single host to complete their lifecycles. Anti-cryptosporidial compounds are generally identified or tested through in vitro phenotypic assays that only assess the asexual stages. Therefore, compounds that specifically target the sexual stages remain unexplored. In this study, we leveraged the ReFRAME drug repurposing library against a newly devised multi-readout imaging assay to identify small-molecule compounds that modulate macrogamont differentiation and maturation. RNA-seq studies confirmed selective modulation of macrogamont differentiation for 10 identified compounds (9 inhibitors and 1 accelerator). The collective transcriptomic profiles of these compounds indicates that translational repression accompanies Cryptosporidium sexual differentiation, which we validated experimentally. Additionally, cross comparison of the RNA-seq data with promoter sequence analysis for stage-specific genes converged on a key role for an Apetala 2 (AP2) transcription factor (cgd2_3490) in differentiation into macrogamonts. Finally, drug annotation for the ReFRAME hits indicates that an elevated supply of energy equivalence in the host cell is critical for macrogamont formation. Cryptosporidium species are intracellular intestinal parasites that cause prolonged diarrhea in immunocompromised people and children. Recent in vitro studies of the Cryptosporidium life cycle indicate the parasite undergoes three rounds of asexual replication followed by an obligatory sexual cycle. This life cycle suggests the novel possibilities of therapy or prevention by targeting sexual differentiation and reproduction. To identify drug-like inhibitors and tool compounds, we developed a screening assay for female gametocytogenesis and screened the ReFRAME library. Our screen identified selective sexual differentiation inhibitors. We then studied the impacts of inhibitor treatment on RNA expression. Comparison of our results to publicly available female-specific gene expression data confirmed that the inhibitors selectively modulated differentiation. We then found that ribosomal protein expression falls during Cryptosporidium female gametocytogenesis, and we experimentally demonstrated corresponding translational repression. Further analysis of promoter regions of coordinately regulated genes implicated a conserved promoter motif and an Apetala 2 transcription factor in female gametocytogenesis. This study identifies a set of tool compounds that selectively modulate Cryptosporidium female gametocytogenesis, provides new insights into female differentiation, and lays the groundwork for future investigations to determine if obligatory sexual reproduction is a vulnerability that can be exploited for therapy or prevention of cryptosporidiosis.

Identification of and Structural Insights into Hit Compounds Targeting N -Myristoyltransferase for Cryptosporidium Drug Development

Structure-Based Virtual Screening, Insilico Docking, ADME Prediction, and Molecular Dynamics Studies for Identification of Potential NMT Inhibitors Against Malaria

Identification of potent and selective N-myristoyltransferase inhibitors of Plasmodium vivax liver stage hypnozoites and schizonts

E-pharmacophore and deep learning based high throughput virtual screening for identification of CDPK1 inhibitors of Cryptosporidium parvum

Identification of potential inhibitors against Inosine 5'-Monophosphate Dehydrogenase of Cryptosporidium parvum through an integrated in silico approach

Homology Modeling and Molecular Dynamics Simulation of N-myristoyltransferase from Protozoan Parasites: Active Site Characterization and Insights into Rational Inhibitor Design

Identification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice

On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target

Cryptosporidium lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacy

Novel Anti-Cryptosporidium Activity of Known Drugs Identified by High-Throughput Screening Against Parasite Fatty Acyl-Coa Binding Protein (ACBP)

Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetases.

Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum

A non-traditional crystal-based compound screening method targeting the ATP binding site of Plasmodium falciparum GRP78 for identification of novel nucleoside analogues

The Cryptosporidium Parvum Kinome

A probable means to an end: exploring P131 pharmacophoric scaffold to identify potential inhibitors of Cryptosporidium parvum inosine monophosphate dehydrogenase

Treating cryptosporidiosis: A review on drug discovery strategies

Exploring N-myristoyltransferase as a promising drug target against parasitic neglected tropical diseases

Discovery of Novel Anti-cryptosporidial Activities from Natural Products by in Vitro High-Throughput Phenotypic Screening

Novel Acyl Carbamates and Acyl/diacyl Ureas Show in Vitro Efficacy Against Toxoplasma Gondii and Cryptosporidium Parvum

Cryptosporidium life cycle small molecule probing implicates translational repression and an Apetala 2 transcription factor in macrogamont differentiation

Target Elucidation by Cocrystal Structures of Nadh-Ubiquinone Oxidoreductase of Plasmodium Falciparum (pfndh2) with Small Molecule to Eliminate Drug-Resistant Malaria